SCHEMBL18977796

SCHEMBL18977796

CC(O)[C@H](O)n1cnc(C(N)=O)n1

nearest known ligand 0.35

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.35
ADORA1 P30542 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 2/20 0.35
GLA P06280 1/20 0.35
EIF4E P06730 1/20 0.35
CYP3A4 P08684 1/20 0.35
TOP1 P11387 1/20 0.35
TSHR P16473 1/20 0.35
THPO P40225 1/20 0.35
PMP22 Q01453 1/20 0.35
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
SLC6A3 Q01959 1/20 0.33
TMEM97 Q5BJF2 1/20 0.33
MAPK1 P28482 1/20 0.33
ADORA2A P29274 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL784347 0.84 ADORA1 (0.40) LMNAADORA1SMN1; SMN2ALDH1A1GLA
SCHEMBL19861815 0.78 ACHE (0.38) LMNAADORA1SMN1; SMN2ALDH1A1GLA
SCHEMBL18750762 0.76 LMNA (0.37) LMNAADORA1SMN1; SMN2ALDH1A1GLA
SCHEMBL12939295 0.76 LMNA (0.37) LMNAADORA1SMN1; SMN2ALDH1A1GLA
SCHEMBL22399607 0.76 ACHE (0.40) LMNAADORA1SMN1; SMN2ALDH1A1GLA
SCHEMBL30587540 0.74 TDP1 (0.42) LMNAALDH1A1CYP3A4MAPK1
SCHEMBL11851306 0.74 LMNA (0.35) LMNAADORA1SMN1; SMN2ALDH1A1GLA
SCHEMBL30587581 0.74 TDP1 (0.42) LMNAALDH1A1CYP3A4MAPK1
SCHEMBL23633811 0.73 LMNA (0.34) LMNAADORA1SMN1; SMN2ALDH1A1GLA
SCHEMBL30092676 0.72 CLK1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170166557-A1 6-SUBSTITUTED QUINAZOLINONE INHIBITORS UNIV KANSAS (US) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166557-A1 6-SUBSTITUTED QUINAZOLINONE INHIBITORS NDUFV3, NDUFV2, NDUFV1 LMNA 1496/4885ADORA1 4019/4885SMN1; SMN2 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.